Table 1.

Baseline characteristics

	Advanced CSCC (N=193)
Median age, years (range)	72.0 (38–96)
Male, n (%)	161 (83.4)
Eastern Cooperative Oncology Group performance status score, n (%)
0	86 (44.6)
1	107 (55.4)
Primary CSCC site: head and neck, n (%)	131 (67.9)
Metastatic CSCC, n (%)	115 (59.6)
Locally advanced CSCC, n (%)	78 (40.4)
Patients with cemiplimab as first-line therapy, n (%)	128 (66.3)
Patients with prior systemic therapy, n (%)*	65 (33.7)
Median duration of exposure to cemiplimab, weeks (range)	51.1 (2.0–109.3)
Median number of doses of cemiplimab administered (range)	18.0 (1–48)

*Settings for prior lines of therapy included metastatic disease, adjuvant, chemotherapy with concurrent radiation, or other, and the most common types of prior systemic therapy were platinum compounds (n=46/65 [70.8%]) and monoclonal antibodies (n=18/65 [27.7%]).

CSCC, cutaneous squamous cell carcinoma.